-
1
-
-
84875804295
-
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
-
Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403
-
(2013)
Eur J Cancer
, vol.49
, pp. 1374-1403
-
-
Ferlay, J.1
Steliarova-Foucher, E.2
Lortet-Tieulent, J.3
-
3
-
-
79955877897
-
Molecular pathogenesis of Hodgkin's lymphoma: Increasing evidence of the importance of the microenvironment
-
Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: Increasing evidence of the importance of the microenvironment. J Clin Oncol 2011;29:1812-26
-
(2011)
J Clin Oncol
, vol.29
, pp. 1812-1826
-
-
Steidl, C.1
Connors, J.M.2
Gascoyne, R.D.3
-
4
-
-
84904647397
-
Nodular lymphocyte predominant Hodgkin Lymphoma: Biology, diagnosis and treatment
-
Epub ahead of print]
-
Goel A, Fan W, Patel AA, et al. Nodular lymphocyte predominant Hodgkin Lymphoma: Biology, diagnosis and treatment. Clin Lymphoma Myeloma Leuk 2014. [Epub ahead of print]
-
(2014)
Clin Lymphoma Myeloma Leuk
-
-
Goel, A.1
Fan, W.2
Patel, A.A.3
-
5
-
-
77956646155
-
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma
-
Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-52
-
(2010)
N Engl J Med
, vol.363
, pp. 640-652
-
-
Engert, A.1
Plutschow, A.2
Eich, H.T.3
-
6
-
-
84860626866
-
Dose-intensification in early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD14 trial
-
von Tresckow B, Plutschow A, Fuchs M, et al. Dose-intensification in early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 2012;30:907-13
-
(2012)
J Clin Oncol
, vol.30
, pp. 907-913
-
-
Von Tresckow, B.1
Plutschow, A.2
Fuchs, M.3
-
7
-
-
84860833364
-
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial
-
Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A randomised, open-label, phase 3 non-inferiority trial. Lancet 2012;379:1791-9
-
(2012)
Lancet
, vol.379
, pp. 1791-1799
-
-
Engert, A.1
Haverkamp, H.2
Kobe, C.3
-
9
-
-
80055064605
-
The role of autologous transplantation in Hodgkin lymphoma
-
von Tresckow B, Engert A. The role of autologous transplantation in Hodgkin lymphoma. Curr Hematol Malig Rep 2011;6:172-9
-
(2011)
Curr Hematol Malig Rep
, vol.6
, pp. 172-179
-
-
Von Tresckow, B.1
Engert, A.2
-
10
-
-
84883333182
-
Identification of prognostic factors predicting outcome in hodgkin's lymphoma patients relapsing after autologous stem cell transplantation
-
Sep
-
Martinez C, Canals C, Sarina B, et al. Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation. Ann Oncol 2013;Sep;24(9):2430-4
-
(2013)
Ann Oncol
, vol.24
, Issue.9
, pp. 2430-2434
-
-
Martinez, C.1
Canals, C.2
Sarina, B.3
-
11
-
-
84902456895
-
Outcome and risk factors of Hodgkin Lymphoma patients who relapse or progress after autologous stem cell transplant
-
Epub ahead of print]
-
von Tresckow B, Muller H, Eichenauer DA, et al. Outcome and risk factors of Hodgkin Lymphoma patients who relapse or progress after autologous stem cell transplant. Leuk Lymphoma 2014. [Epub ahead of print]
-
(2014)
Leuk Lymphoma
-
-
Von Tresckow, B.1
Muller, H.2
Eichenauer, D.A.3
-
12
-
-
84894356294
-
Relapsed Hodgkin Lymphoma in older patients: A comprehensive analysis from the German Hodgkin Study Group
-
31
-
Boll B, Goergen H, Arndt N, et al. Relapsed Hodgkin Lymphoma in older patients: A comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2013;10;31(35):4431-7
-
(2013)
J Clin Oncol
, vol.10
, Issue.35
, pp. 4431-4437
-
-
Boll, B.1
Goergen, H.2
Arndt, N.3
-
13
-
-
78049515807
-
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas
-
Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-21
-
(2010)
N Engl J Med
, vol.363
, pp. 1812-1821
-
-
Younes, A.1
Bartlett, N.L.2
Leonard, J.P.3
-
14
-
-
84863676500
-
Results of a pivotal phase II study of Brentuximab Vedotin for patients with relapsed or refractory Hodgkin's Lymphoma
-
Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of Brentuximab Vedotin for patients With relapsed or refractory Hodgkin's Lymphoma. J Clin Oncol 2012;30:2183-9
-
(2012)
J Clin Oncol
, vol.30
, pp. 2183-2189
-
-
Younes, A.1
Gopal, A.K.2
Smith, S.E.3
-
15
-
-
84856421828
-
Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory hodgkin's lymphoma results of the hdr-Allo study-A prospective clinical trial by the grupo espanol de linfomas/trasplante de medula osea (gel/tamo) and the lymphoma working party of the european group for blood and marrow transplantation
-
Sureda A, Canals C, Arranz R, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study-A prospective clinical trial by the Grupo Espanol de Linfomas/Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica 2012;97:310-17
-
(2012)
Haematologica
, vol.97
, pp. 310-317
-
-
Sureda, A.1
Canals, C.2
Arranz, R.3
-
16
-
-
0242579150
-
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma
-
DOI 10.1182/blood-2003-02-0515
-
Borchmann P, Treml JF, Hansen H, et al. The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 2003;102:3737-42 (Pubitemid 37409395
-
(2003)
Blood
, vol.102
, Issue.10
, pp. 3737-3742
-
-
Borchmann, P.1
Treml, J.F.2
Hansen, H.3
Gottstein, C.4
Schnell, R.5
Staak, O.6
Zhang, H.-F.7
Davis, T.8
Keler, T.9
Diehl, V.10
Graziano, R.F.11
Engert, A.12
-
17
-
-
34447573999
-
Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma
-
DOI 10.1200/JCO.2006.07.8972
-
Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 2007;25:2764-9 (Pubitemid 47123185
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.19
, pp. 2764-2769
-
-
Ansell, S.M.1
Horwitz, S.M.2
Engert, A.3
Khan, K.D.4
Lin, T.5
Strair, R.6
Keler, T.7
Graziano, R.8
Blanset, D.9
Yellin, M.10
Fischkoff, S.11
Assad, A.12
Borchmann, P.13
-
18
-
-
84899107870
-
Three-year follow-up data and characterization of long-Term remissions from an ongoing phase 2 study of Brentuximab Vedotin in patients with relapsed or refractory Hodgkin Lymphoma
-
Chen R, Smith SE, Ansell SM, et al. Three-year follow-up data and characterization of long-Term remissions from an ongoing phase 2 study of Brentuximab Vedotin in patients with relapsed or refractory Hodgkin Lymphoma. Blood 2013;122:4382
-
(2013)
Blood
, vol.122
, pp. 4382
-
-
Chen, R.1
Smith, S.E.2
Ansell, S.M.3
-
19
-
-
84888138217
-
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: A phase 1, open-label, dose-escalation study
-
Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: A phase 1, open-label, dose-escalation study. Lancet Oncol 2013;14:1348-56
-
(2013)
Lancet Oncol
, vol.14
, pp. 1348-1356
-
-
Younes, A.1
Connors, J.M.2
Park, S.I.3
-
20
-
-
84900794661
-
Targeted Beacopp variants in patients with newly diagnosed advanced stage classical Hodgkin Lymphoma: Interim results of a randomized phase II study
-
Eichenauer DA, Plütschow A, Kreissl S, et al. Targeted Beacopp variants in patients with newly diagnosed advanced stage classical Hodgkin Lymphoma: Interim results of a randomized phase II study. Blood 2013;122:4344
-
(2013)
Blood
, vol.122
, pp. 4344
-
-
Eichenauer, D.A.1
Plütschow, A.2
Kreissl, S.3
-
21
-
-
84863522501
-
Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma
-
Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood 2012;119:6379-81
-
(2012)
Blood
, vol.119
, pp. 6379-6381
-
-
Chen, R.1
Palmer, J.M.2
Thomas, S.H.3
-
22
-
-
84875672985
-
Brentuximab vedotin in refractory CD30 + lymphomas: A bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center
-
Gibb A, Jones C, Bloor A, et al. Brentuximab vedotin in refractory CD30 + lymphomas: A bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica 2013;98:611-14
-
(2013)
Haematologica
, vol.98
, pp. 611-614
-
-
Gibb, A.1
Jones, C.2
Bloor, A.3
-
23
-
-
82555187781
-
Mocetinostat for relapsed classical Hodgkin's lymphoma: An open-label, single-Arm, phase 2 trial
-
Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin's lymphoma: An open-label, single-Arm, phase 2 trial. Lancet Oncol 2011;12:1222-8
-
(2011)
Lancet Oncol
, vol.12
, pp. 1222-1228
-
-
Younes, A.1
Oki, Y.2
Bociek, R.G.3
-
24
-
-
84864024420
-
Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: Results of a phase II study
-
Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: Results of a phase II study. J Clin Oncol 2012;30:2197-203
-
(2012)
J Clin Oncol
, vol.30
, pp. 2197-2203
-
-
Younes, A.1
Sureda, A.2
Ben-Yehuda, D.3
-
25
-
-
84901290049
-
A phase i study of panobinostat in combination with ice (ifosfamide, carboplatin and etoposide in patients with relapsed or refractory classical hodgkin lymphoma (chl)
-
Fanale MA, Westin JR, Fowler N, et al. A phase I study of Panobinostat in combination with ICE (Ifosfamide, Carboplatin and Etoposide) in patients with relapsed or refractory Classical Hodgkin Lymphoma (cHL). Blood 2013;122:252
-
(2013)
Blood
, vol.122
, pp. 252
-
-
Fanale, M.A.1
Westin, J.R.2
Fowler, N.3
-
26
-
-
84898410834
-
A phase iii randomized double blind placebo controlled multi-center study of panobinostat for maintenance of response in patients with hodgkin lymphoma who are at risk for relapse after high dose chemotherapy and autologous stem cell transplant: Final results after early trial discontinuation
-
von Tresckow B, Skotnicki A, Lisukov I, et al. A phase III randomized, double blind, placebo controlled multi-center study of Panobinostat for maintenance of response in patients with Hodgkin Lymphoma who are at risk for relapse after high dose chemotherapy and autologous stem cell transplant: Final results after early trial discontinuation. Blood 2013;21;122:4648
-
(2013)
Blood
, vol.21
, Issue.122
, pp. 4648
-
-
Von Tresckow, B.1
Skotnicki, A.2
Lisukov, I.3
-
27
-
-
23944453915
-
A rapamycin derivative (everolimus) controls proliferation through down-regulation of truncated CCAAT enhancer binding protein beta and NF-betaB activity in Hodgkin and anaplastic large cell lymphomas
-
DOI 10.1182/blood-2004-11-4513
-
Jundt F, Raetzel N, Muller C, et al. A rapamycin derivative (everolimus) controls proliferation through downregulation of truncated CCAAT enhancer binding protein {beta} and NF-{kappa}B activity in Hodgkin and anaplastic large cell lymphomas. Blood 2005;106:1801-7 (Pubitemid 41208597
-
(2005)
Blood
, vol.106
, Issue.5
, pp. 1801-1807
-
-
Jundt, F.1
Raetzel, N.2
Muller, C.3
Calkhoven, C.F.4
Kley, K.5
Mathas, S.6
Lietz, A.7
Leutz, A.8
Dorken, B.9
-
28
-
-
77951559617
-
A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma
-
Johnston PB, Inwards DJ, Colgan JP, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010;85(5):320-4
-
Am J Hematol 2010
, vol.85
, Issue.5
, pp. 320-324
-
-
Johnston, P.B.1
Inwards, D.J.2
Colgan, J.P.3
-
29
-
-
84976593783
-
Phase 2 study of everolimus for relapsed/refractory classical Hodgkin Lymphoma (cHL
-
Johnston P, Pinter-Brown L, Rogerio J, et al. Phase 2 study of everolimus for relapsed/refractory classical Hodgkin Lymphoma (cHL). Haematologica 2013;98:1-64
-
(2013)
Haematologica
, vol.98
, pp. 1-64
-
-
Johnston, P.1
Pinter-Brown, L.2
Rogerio, J.3
-
30
-
-
84890606231
-
Phase i study of Panobinostat plus Everolimus in patients with relapsed or refractory Lymphoma
-
Oki Y, Buglio D, Fanale M, et al. Phase I study of Panobinostat plus Everolimus in patients with relapsed or refractory Lymphoma. Clin Cancer Res 2013;19:6882-90
-
(2013)
Clin Cancer Res
, vol.19
, pp. 6882-6890
-
-
Oki, Y.1
Buglio, D.2
Fanale, M.3
-
31
-
-
84877095601
-
Molecular pathways: Jak/STAT pathway: Mutations, inhibitors, and resistance
-
Quintas-Cardama A, Verstovsek S. Molecular pathways: Jak/STAT pathway: Mutations, inhibitors, and resistance. Clin Cancer Res 2013;19:1933-40
-
(2013)
Clin Cancer Res
, vol.19
, pp. 1933-1940
-
-
Quintas-Cardama, A.1
Verstovsek, S.2
-
32
-
-
84875334036
-
New insights in the biology of Hodgkin lymphoma
-
Kuppers R. New insights in the biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2012;2012:328-34
-
(2012)
Hematology Am Soc Hematol Educ Program
, vol.2012
, pp. 328-334
-
-
Kuppers, R.1
-
33
-
-
79955394571
-
Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis
-
Diaz T, Navarro A, Ferrer G, et al. Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis. PLoS One 2011;6:e18856
-
(2011)
PLoS One
, vol.6
-
-
Diaz, T.1
Navarro, A.2
Ferrer, G.3
-
34
-
-
84869401524
-
Phase i study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: Evidence of clinical and biologic activity in multiple lymphoma subtypes
-
Younes A, Romaguera J, Fanale M, et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: Evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin Oncol 2012;30:4161-7
-
(2012)
J Clin Oncol
, vol.30
, pp. 4161-4167
-
-
Younes, A.1
Romaguera, J.2
Fanale, M.3
-
35
-
-
81055123994
-
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
-
Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011;118:5119-25
-
(2011)
Blood
, vol.118
, pp. 5119-5125
-
-
Fehniger, T.A.1
Larson, S.2
Trinkaus, K.3
-
36
-
-
84875924110
-
A Phase 2 multicenter Study of continuous dose Lenalidomide in relapsed or refractory classical Hodgkin Lymphoma
-
2012 November 16
-
Fehniger TA, Larson S, Trinkaus K, et al. A Phase 2 multicenter Study of continuous dose Lenalidomide in relapsed or refractory classical Hodgkin Lymphoma. ASH Annual Meeting Abstracts 2012 November 16 2012;120:1623
-
(2012)
ASH Annual Meeting Abstracts
, vol.120
, pp. 1623
-
-
Fehniger, T.A.1
Larson, S.2
Trinkaus, K.3
-
37
-
-
74049104854
-
Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma
-
Boll B, Borchmann P, Topp MS, et al. Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. Br J Haematol 2010;148:480-2
-
(2010)
Br J Haematol
, vol.148
, pp. 480-482
-
-
Boll, B.1
Borchmann, P.2
Topp, M.S.3
-
38
-
-
84900831378
-
German hodgkin study group phase i trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for older hodgkin lymphoma patients
-
Boll B, Plütschow A, Fuchs M, et al. German hodgkin study group phase I trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for older hodgkin lymphoma patients. Blood 2013;122:3054
-
(2013)
Blood
, vol.122
, pp. 3054
-
-
Boll, B.1
Plütschow, A.2
Fuchs, M.3
-
39
-
-
77958490178
-
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcgammaRIIIa-158 V/F polymorphism
-
Blum KA, Jung SH, Johnson JL, et al. Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcgammaRIIIa-158 V/F polymorphism. Ann Oncol 2010;21:2246-54
-
(2010)
Ann Oncol
, vol.21
, pp. 2246-2254
-
-
Blum, K.A.1
Jung, S.H.2
Johnson, J.L.3
|